LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Tsourouflis, Gerassimos"
  2. AU="Srai, S K"
  3. AU="Or, Charles C-F"
  4. AU="Rohin, Francis"
  5. AU="Natália Pinto de Almeida"
  6. AU="Spagnolo-Allende, Antonio J"
  7. AU="Jenninger, B"
  8. AU="Kerenza Hood"
  9. AU="Khan Chachar, Aijaz Zeeshan"
  10. AU="Yuan, Weiming"

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: A Case Report of Chronic Myelogenous Leukemia Presenting as Blastic Crisis with a T-Cell Acute Lymphoblastic Leukemia Phenotype: Awareness of a Rare Entity.

    Efstathopoulou, Maria / Zoi, Katerina / Siakantaris, Marina P / Koumbi, Daphne / Zannou, Anna / Triantafyllou, Evangelia-Faidra / Tsourouflis, Gerassimos / Lakiotaki, Eleftheria / Vassilakopoulos, Theodoros P / Angelopoulou, Maria K

    Acta haematologica

    2023  Volume 146, Issue 6, Page(s) 530–537

    Abstract: Chronic myelogenous leukemia at blast crisis with a T-cell phenotype (T-ALL CML-BC) at diagnosis, without any prior history of CML is extremely rare. After the introduction of tyrosine kinase inhibitors (TKIs), CML patients have a median survival ... ...

    Abstract Chronic myelogenous leukemia at blast crisis with a T-cell phenotype (T-ALL CML-BC) at diagnosis, without any prior history of CML is extremely rare. After the introduction of tyrosine kinase inhibitors (TKIs), CML patients have a median survival comparable to general population and accelerated/blast crisis are rarely encountered. Most CML patients (80%) transform into acute myeloid leukemia and the rest into B-ALL. Anecdotal cases of Ph+ T-ALL, either de novo or in the context of CML-BC have been reported. Left shift in the blood, the presence of splenomegaly/extramedullary infiltration and the occurrence of BCR::ABL1 rearrangement in both the blastic population, as well as in the myeloid cell compartment are key points in differentiating de novo Ph+ T-ALL from T-ALL CML-BC. The latter is a rare entity, characterized by extramedullary disease, p210 transcript and clonal evolution. Lack of preceding CML does not rule out the diagnosis of T-ALL CML-BC. Prompt TKI treatment with ALL-directed therapy followed by allogeneic stem cell transplantation may offer long-term survival in this otherwise poor prognosis entity. In this paper, we describe a patient with T-ALL CML-BC at presentation, still alive 51 months after diagnosis and we offer a review of the literature on this rare subject. All clinical and laboratory features are provided in order to distinguish de novo Ph+ T-ALL from T-ALL CML-BC, underscoring the prognostic and therapeutic significance of such a differentiation.
    MeSH term(s) Humans ; Blast Crisis/therapy ; Blast Crisis/genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy ; Phenotype ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/therapy ; T-Lymphocytes
    Language English
    Publishing date 2023-08-09
    Publishing country Switzerland
    Document type Review ; Case Reports
    ZDB-ID 80008-9
    ISSN 1421-9662 ; 0001-5792
    ISSN (online) 1421-9662
    ISSN 0001-5792
    DOI 10.1159/000529911
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Prognostic Impact of Serum β

    Vassilakopoulos, Theodoros P / Arapaki, Maria / Diamantopoulos, Panagiotis T / Liaskas, Athanasios / Panitsas, Fotios / Siakantaris, Marina P / Dimou, Maria / Kokoris, Styliani I / Sachanas, Sotirios / Belia, Marina / Chatzidimitriou, Chrysovalantou / Konstantinou, Elianna A / Asimakopoulos, John V / Petevi, Kyriaki / Boutsikas, George / Kanellopoulos, Alexandros / Piperidou, Alexia / Lefaki, Maria-Ekaterini / Georgopoulou, Angeliki /
    Kopsaftopoulou, Anastasia / Zerzi, Kalliopi / Drandakis, Ioannis / Dimopoulou, Maria N / Kyrtsonis, Marie-Christine / Tsaftaridis, Panayiotis / Plata, Eleni / Variamis, Eleni / Tsourouflis, Gerassimos / Kontopidou, Flora N / Konstantopoulos, Kostas / Pangalis, Gerassimos A / Panayiotidis, Panayiotis / Angelopoulou, Maria K

    Cancers

    2024  Volume 16, Issue 2

    Abstract: The significance of serum beta-2 microglobulin ( ... ...

    Abstract The significance of serum beta-2 microglobulin (sβ
    Language English
    Publishing date 2024-01-05
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers16020238
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.

    Spathas, Nikolaos / Belia, Marina / Giannikos, Theofanis / Arapaki, Maria / Efstathopoulou, Maria / Tsourouflis, Gerassimos / Gainaru, Gabriella / Asimakopoulos, John / Tsaftaridis, Panayiotis / K Angelopoulou, Maria / Plata, Eleni / Konstantopoulos, Kostas / P Vassilakopoulos, Theodoros

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology

    2020  Volume 24, Issue 6, Page(s) 2483–2489

    Abstract: Purpose: To present our experience on the use of Brentuximab Vedotin (BV) in patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) and severe liver function impairment with marked jaundice.: Methods: Two patients with relapsed/refractory ...

    Abstract Purpose: To present our experience on the use of Brentuximab Vedotin (BV) in patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) and severe liver function impairment with marked jaundice.
    Methods: Two patients with relapsed/refractory cHL were evaluated. BV was administered in the presence of liver dysfunction and severe jaundice due to liver infiltration by cHL, as confirmed by PET-CT. Complete blood counts, biochemical profile, physical and imaging findings were reviewed to assess BV efficacy and tolerance.
    Results: Case 1 had stage IVB, mixed cellularity cHL. Following ABVD chemotherapy, the patient experienced a relapse and responded to IGEV (ifosfamide, gemcitabine, vinorelbine, steroids) chemotherapy followed by autologous stem cell transplantation (ASCT). Thereafter, he experienced a second relapse with constitutional symptoms, severe jaundice and pancytopenia. Liver involvement was confirmed by PET-CT. Case 2 was admitted with a very late relapse of cHL. After a single cycle of gemcitabine-vinorelbine chemotherapy, which was not tolerated, the patient developed fever, anemia and jaundice, with laboratory findings indicating bone marrow and liver infiltration. The latter was confirmed by PET-CT. Both patients received BV monotherapy according to its formal indication at the reduced dose of 1.2 mg/kg due to severe liver impairment and experienced a rapid clinical and laboratory improvement. BV was well tolerated and offered a clinical benefit for approximately 4 months.
    Conclusions: BV was safely administered to patients with relapsed/refractory cHL and severe liver function impairment with marked jaundice due to liver involvement, offering significant clinical improvement and reversal of liver abnormalities. BV may serve as a bridge to further salvage combination chemotherapy or a transplant procedure.
    MeSH term(s) Adult ; Aged ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Brentuximab Vedotin/therapeutic use ; Drug Resistance, Neoplasm/drug effects ; Hodgkin Disease/drug therapy ; Hodgkin Disease/pathology ; Humans ; Liver Diseases/etiology ; Liver Diseases/pathology ; Liver Diseases/prevention & control ; Male ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Retrospective Studies
    Chemical Substances Antineoplastic Agents, Immunological ; Brentuximab Vedotin (7XL5ISS668)
    Language English
    Publishing date 2020-01-25
    Publishing country Greece
    Document type Case Reports ; Journal Article
    ZDB-ID 2040386-0
    ISSN 2241-6293 ; 1107-0625
    ISSN (online) 2241-6293
    ISSN 1107-0625
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Curative surgery in highly selected patients with heavily pretreated, relapsed/refractory classical Hodgkin lymphoma.

    Papadakis, Vassilios / Efstathopoulou, Maria / Angelopoulou, Maria K / Tsourouflis, Gerassimos / Prassopoulos, Vassilios / Rondogianni, Phivi / Kourtesis, Antonios / Polychronopoulou, Sophia / Pangalis, Gerassimos A / Vassilakopoulos, Theodoros P

    Leukemia & lymphoma

    2020  Volume 62, Issue 3, Page(s) 722–726

    MeSH term(s) Hodgkin Disease/drug therapy ; Hodgkin Disease/surgery ; Humans ; Lymphoma, Non-Hodgkin
    Language English
    Publishing date 2020-11-25
    Publishing country United States
    Document type Letter
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2020.1842404
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?

    Vassilakopoulos, Theodoros P / Piperidou, Alexia / Mellios, Zois / Verigou, Evgenia / Katodritou, Eirini / Kalpadakis, Christina / Papageorgiou, Sotirios G / Chatzidimitriou, Chrysovalantou / Prassopoulos, Vassilios / Siakantaris, Marina P / Giatra, Hara / Karantanis, Dimitrios / Papathanasiou, Nikolaos / Ligdi, Loukia / Kopsaftopoulou, Anastasia / Leonidopoulou, Theoni / Xanthopoulos, Vasileios / Karakatsanis, Stamatios / Vrakidou, Effimia /
    Chatziioannou, Sophia / Drougkas, Dimitrios / Hatzimichael, Eleftheria / Gainaru, Gabriella / Palassopoulou, Maria / Tsirogianni, Maria / Kotsopoulou, Maria / Tsourouflis, Gerassimos / Skoura, Evangelia / Mainta, Catherine / Terpos, Evangelos / Poziopoulos, Christos / Triantafyllou, Theodora / Zikos, Panayiotis / Koumarianou, Argyro / Liapi, Dimitra / Pappa, Vassiliki / Verrou, Evgenia / Tsirigotis, Panayiotis / Labropoulou, Vassiliki / Papadaki, Helen / Datseris, Ioannis / Symeonidis, Argiris / Bouzani, Maria / Bakiri, Maria / Karmiris, Themis / Angelopoulou, Maria K / Rondogianni, Phivi

    HemaSphere

    2023  Volume 7, Issue 11, Page(s) e965

    Language English
    Publishing date 2023-11-07
    Publishing country United States
    Document type Journal Article
    ISSN 2572-9241
    ISSN (online) 2572-9241
    DOI 10.1097/HS9.0000000000000965
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma.

    Karakatsanis, Stamatis J / Bouzani, Maria / Symeonidis, Argyris / Angelopoulou, Maria K / Papageorgiou, Sotirios G / Michail, Michail / Gainaru, Gabriella / Kourti, Georgia / Sachanas, Sotirios / Kalpadakis, Christina / Katodritou, Eirini / Leonidopoulou, Theoni / Kotsianidis, Ioannis / Hatzimichael, Eleftheria / Kotsopoulou, Maria / Dimou, Maria / Variamis, Eleni / Boutsis, Dimitrios / Kanellias, Nick /
    Dimopoulou, Maria N / Michali, Evridiki / Karianakis, George / Tsirkinidis, Pantelis / Vadikolia, Chryssa / Poziopoulos, Christos / Pigaditou, Anna / Vrakidou, Effimia / Economopoulos, Theophanis / Kyriazopoulou, Lydia / Siakantaris, Marina P / Kyrtsonis, Marie-Christine / Anargyrou, Konstantinos / Papaioannou, Maria / Hatjiharissi, Evdoxia / Vervessou, Elissavet / Tsirogianni, Maria / Palassopoulou, Maria / Stefanoudaki, Ekaterini / Zikos, Panayiotis / Tsirigotis, Panayiotis / Tsourouflis, Gerassimos / Assimakopoulou, Theodora / Verrou, Evgenia / Papadaki, Helen / Lampropoulou, Polixeni / Dimopoulos, Meletios-Athanasios / Pappa, Vassiliki / Konstantopoulos, Kostas / Karmiris, Themis / Roussou, Paraskevi / Panayiotidis, Panayiotis / Pangalis, Gerassimos A / Vassilakopoulos, Theodoros P

    In vivo (Athens, Greece)

    2022  Volume 36, Issue 3, Page(s) 1302–1315

    Abstract: Background/aim: Primary mediastinal large B-cell lymphoma (PMLBCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20 monoclonal antibody rituximab into current therapeutic ... ...

    Abstract Background/aim: Primary mediastinal large B-cell lymphoma (PMLBCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20 monoclonal antibody rituximab into current therapeutic regimens. Evidence, however, on the optimal time interval between consecutive chemoimmunotherapy (CIT) cycles is still scarce. This study aimed to evaluate the efficacy outcomes of the more commonly administered 3-weekly regimens to the biweekly ones in a PMLBCL patients' population, who were mostly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP-21) or R-CHOP-14.
    Patients and methods: We retrospectively studied our cohort of consecutively treated PMLBCL patients, focusing on their treatment density, in order to determine possible differences in treatment outcomes.
    Results: CIT, in the form of both R-CHOP-21 as well as R-CHOP-14 (or similar regimens), is highly active in PMLBCL, with low rates of early treatment failure. In our cohort of patients, R-CHOP-14 did not result in a meaningful improvement of freedom from progression (FFP) or overall survival (OS).
    Conclusion: Both R-CHOP-14 and R-CHOP-21 are probably equally effective in PMLBCL, yet further, prospective, randomized studies are warranted to clarify whether dose-dense regimens can be associated with better disease control and long-term results.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cyclophosphamide/therapeutic use ; Doxorubicin ; Humans ; Lymphoma, B-Cell/drug therapy ; Prednisone/therapeutic use ; Prospective Studies ; Retrospective Studies ; Rituximab/therapeutic use ; Vincristine/therapeutic use
    Chemical Substances Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P) ; Prednisone (VB0R961HZT)
    Language English
    Publishing date 2022-04-27
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 807031-3
    ISSN 1791-7549 ; 0258-851X
    ISSN (online) 1791-7549
    ISSN 0258-851X
    DOI 10.21873/invivo.12831
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database.

    Vassilakopoulos, Theodoros P / Piperidou, Alexia / Hadjiharissi, Evdoxia / Panteliadou, Alkistis-Kyra / Panitsas, Fotios / Vassilopoulos, Ioannis / Variamis, Eleni / Boutsis, Dimitrios / Michail, Michail / Papageorgiou, Sotirios / Tsourouflis, Gerassimos / Dimou, Maria / Karakatsanis, Stamatis / Kalpadakis, Christina / Stavroyianni, Niki / Katodritou, Eirini / Kotsopoulou, Maria / Kotsianidis, Ioannis / Verigou, Evgenia /
    Hatzimichael, Eleftheria / Leonidopoulou, Theoni / Xanthopoulos, Vassilios / Panayiotidis, Panayiotis / Konstantopoulos, Kostas / Dimopoulos, Meletios-Athanassios / Karmiris, Themistoklis / Batsis, Ioannis / Papaioannou, Maria / Pangalis, Gerassimos A / Angelopoulou, Maria K

    Leukemia research

    2020  Volume 100, Page(s) 106479

    MeSH term(s) Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Databases, Factual ; Female ; Follow-Up Studies ; Hodgkin Disease/chemically induced ; Hodgkin Disease/pathology ; Humans ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Large B-Cell, Diffuse/pathology ; Male ; Mediastinal Neoplasms/drug therapy ; Mediastinal Neoplasms/pathology ; Prognosis ; Survival Rate
    Language English
    Publishing date 2020-11-16
    Publishing country England
    Document type Letter
    ZDB-ID 752396-8
    ISSN 1873-5835 ; 0145-2126
    ISSN (online) 1873-5835
    ISSN 0145-2126
    DOI 10.1016/j.leukres.2020.106479
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.

    Kalpadakis, Christina / Pangalis, Gerassimos A / Sachanas, Sotirios / Tsirkinidis, Pantelis / Kontopidou, Flora N / Moschogiannis, Maria / Yiakoumis, Xanthi / Koulieris, Efstathios / Dimopoulou, Maria N / Kokkoris, Stella I / Kyrtsonis, Marie-Christine / Siakantaris, Marina P / Tsourouflis, Gerassimos / Korkolopoulou, Penelope / Rontogianni, Dimitra / Tsaftaridis, Panagiotis / Plata, Eleni / Papadaki, Helen A / Panagiotidis, Panagiotis /
    Angelopoulou, Maria K / Vassilakopoulos, Theodoros P

    Blood

    2018  Volume 132, Issue 6, Page(s) 666–670

    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/therapeutic use ; Drug Administration Schedule ; Drug Evaluation ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Lymphoma, B-Cell, Marginal Zone/drug therapy ; Maintenance Chemotherapy ; Male ; Middle Aged ; Progression-Free Survival ; Remission Induction ; Retrospective Studies ; Rituximab/therapeutic use ; Splenic Neoplasms/drug therapy ; Treatment Outcome
    Chemical Substances Antineoplastic Agents, Immunological ; Rituximab (4F4X42SYQ6)
    Language English
    Publishing date 2018-06-18
    Publishing country United States
    Document type Letter
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2018-02-833608
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top